RE:Idle Morning ThoughtsI sense a letdown by posters here, after the realization that ONC is hiring a CRO to manage the P3. CRO's are commonly found managing small biotech companies with the hope that their expertise will channel their drug toward commercialization faster and more efficiently. Are we to assume because of this new development that a buyout is not possible until they conclude their study. I wonder how a contract would read in regard to involvement by big Pharma. Is it a possibility that a potential buyer suggested taking this route? I have no clue. Anything is possible, I guess. We need some clarity